cyrilzakka/clinical-trials huggingface dataset:
Cooking Classes for Chinese Canadian Patients Living With Diabetes

This study aims to determine whether providing language and culturally appropriate cooking classes to Chinese Canadian individuals with diabetes will help to improve their diabetes control, knowledge and self care activities. The control group will receive current standard care of two diabetes education classes led by the dietitian and nurse. The intervention group will receive standard care and a series of four interactive cooking classes led by a dietitian, nurse and chef. We will compare the results of blood work, knowledge and self care questionnaires between the two groups to determine whether there are any benefits to attending these cooking classes.

This is a study attempting to investigate whether a cooking class intervention will lead to improved glycemic control in Chinese-Canadian people in the community of Richmond, British Columbia. By providing culturally appropriate cooking classes, tailored to Chinese foods, culture and population, we will be able to address specific challenges that affect ethnic Chinese patients with diabetes living in Canada. This innovative program would serve to meet a need that is currently unmet in the community, by providing a hands-on opportunity for participants to try different foods, learn various culturally appropriate recipes, prepare meals together and learn how the foods being eaten affects blood glucose. These classes would also serve as an avenue to reinforce various diabetes self-management activities - including self-monitoring of blood glucose and the effects of physical activity. Also, participants may benefit from peer support and the sharing of experiences and advice with each other. Through this research study, we hope to demonstrate improved diabetes knowledge, self-care management and glycemic control for patients who attend the cooking classes.

Eligibility Criteria:
Inclusion Criteria:

1. Enrolled in Type 2 Diabetes Education class in Mandarin or Cantonese at the Richmond Hospital Diabetes Education Centre.
2. Ability to understand and participate in all scheduled diabetes education classes and/or cooking classes;
3. Ability to complete the study questionnaires and standard of care glycemic bloodwork
4. Prior diagnosis of diabetes mellitus type 2
5. Persons who identify as chinese-canadian

Exclusion Criteria for this study includes:

1. Inability to provide informed consent;
2. Planned changes to diabetes medications during the study period, for example insulin titrations or oral medication adjustments;
3. Currently enrolled in another study involving interventions related to diabetes care and management
Nurse-led Clinics Training Program on Mild Cognitive Impairment Patients

This trail is the first study to test the efficacy of nurse-led clinics cognitive training on mild cognitive impairment (MCI) patients using a single-blind, randomized controlled trial design. The investigators hypothesize that nurse-led clinics cognitive training can (a)decelerate or ameliorate cognitive decline, (b)ameliorate anxiety and depressive symptoms, (c)increase the quality of life for both patients and family members, (d)improve the ability of daily life, (e)reduce the incidence of agitation.

Introduction: Globally, nurse-led clinics(NLCs) have been developed to serve and follow up on patients who have just been discharged from the hospital. NLCs cognitive training program as a potentially effective and promising treatment for MCI patients.

Methods: The study is a single-blind, randomized-controlled trial. Eligible patients need to be diagnosed as MCI. Participants will be randomized into either a NLCs training group or a home-based training group. Both groups will undergo total 72hour across 12 months. The outcome measures will be assessed at baseline, at the 6 months and 12 months during the intervention. The primary outcome is global cognitive function, assessed by the 30-item the Mini-Mental State Examination (MMSE), and the secondary outcomes include changes in other neuropsychological assessments and in result of resting electroencephalography (EEG) .

Results: The trial is currently ongoing, and it is anticipated that recruitment will be completed in June 2025.

Discussion: This trial will evaluate the efficacy and safety of NLCs cognitive training in patients with MCI, and further explore the potential mechanisms by analyzing teh results of neuropsychological assessments and EEG.

Eligibility Criteria:
Inclusion Criteria:

* Subjects with informed consent;
* Literate Han Chinese, above the age of 18;
* At least 6 years of education;
* Neither normal nor demented according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, with a Clinical Dementia Rating(CDR) ≥0.5 on at least one domain and a global score ≤0.5; a Mini-Menta State Examination score ≥20 (primary school), or ≥24 (junior school or above).
* having normal vision and hearing with/without corrective devices.

Exclusion Criteria:

* Severe aphasia, physical disabilities, or any other factor that might preclude completion of neuropsychological testing.
* Clinically significant gastrointestinal, renal, hepatic, respiratory, infectious, endocrine, or cardiovascular system disease; cancer; alcoholism; drug addiction.
* Illnesses affecting mobility or are unable to accept assessments or interventions that are required in this study.
Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain

This project addresses a vexing problem that has alluded the best efforts of the medical/scientific community: treatment of resistant neuropathic pain. Neuropathic pain is common and includes conditions such as diabetic neuropathy, post herpetic neuralgia and post stroke pain and is believed to affect at least 3% of adults. Surveys of patients with neuropathic pain indicate that 60% do not receive adequate relief with current treatment. Results from recent laboratory and human studies reveal a new approach to treatment. This approach is based on the findings that neuroinflammation appears to be involved in development and maintenance of neuropathic pain. This study explores the effects of an immune-modulating blood-derived product, intravenous immunoglobulin (IVIG), in treating neuropathic pain. IVIG is thought to reduce neuroinflammation contributing to neuropathic pain. If successful, the study will provide important insights into pain mechanisms and a better understanding of how IVIG relieves neuropathic pain.

Hypotheses:

1. Reduction in neuroinflammation (NI) markers will co-vary with clinical indicators of pain relief
2. Patients with higher levels of markers of NI will be more likely to respond to IVIG

This study will employ a randomized double blind cross-over design. A total of 12 subjects will be recruited for the study. Once each subject has satisfied the inclusion and exclusion criteria and provided informed consent, the subject will be randomized to either the IVIG or placebo treatment groups, using a pre-determined randomization list generated by the research office at the University of Calgary. Complete responders will begin a monitoring phase, partial and non-responders will return for a second cycle in one month. Complete responders, with prolonged relief, will cross-over to the alternative treatment when their pain returns if this occurs within 6 months of the infusion.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years; Clinical diagnosis of treatment-resistant neuropathic pain;
* Score of 4/10 or greater on the DN4 NeP screening questionnaire;
* Bedside examination confirming symptoms of neuropathic pain;
* Moderate to severe pain;
* Completed adequate analgesic trials according to neuropathic pain clinical practice guidelines;
* provides informed consent

Exclusion Criteria:

* Pregnant or lactating women;
* Clinical diagnosis of phantom limb pain;
* History of psychosis;
* current, substance dependency disorder;
* presence of clinically significant cardiac or pulmonary disorder that would compromise participants' safety;
* severe pain disorder other than the chronic NeP under study;
* Abnormalities above 1.5 times upper range of normal on screening CBC, blood chemistry;
* Serum IgA less than \<0.05 g/L
Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy

To determine the optimal time for the Tenofovir treatment of anti-Hepatitis B Virus (HBV) during the pregnancy among women with chronic HBV infection and high HBV DNA load. This is a randomized, open-label, three-arms, parallel-controlled clinical trial. Pregnant women with high HBV load and normal liver function will be treated with tenofovir during the middle or late stage of pregnancy, started from 24th gestational week, 28th gestational week and 32th gestational week through 1 month postpartum, respectively. The HBV DNA load at 40th gestational week of mothers, the intrauterine HBV infection rate of infants will be compared across the three groups.

Tenofovir Disoproxil Fumarate is a American Food and Drug Administration (FDA) pregnancy class B drug. To determine the optimal time for the tenofovir treatment during the pregnancy among women with chronic HBV infection and high HBV DNA load. Pregnant women with high HBV DNA load and normal liver function at second trimester will be randomized into three treatment groups at the 20th week of gestation and treated with tenofovir from 24 weeks, 28 weeks and 32 weeks to 1 month postpartum, respectively. The blood will be drawn at 24 weeks, 28 weeks, 32 weeks, 36 weeks and the delivery, respectively and the HBV DNA load and liver functions will be tested. The status of HBV infection for infants will be observed at 1st month, 7th month and 12th month after the babies were delivered. The HBV DNA load at 40th gestational week of mothers, the intrauterine HBV infection rate of infants and safety outcomes will be compared across the three groups.

Eligibility Criteria:
Inclusion Criteria:

* Women between 20 and 40 years old
* Have had HBsAg positive in serum greater than 6 months
* HBV DNA load\>10\*\*6 IU/ml
* Gestation week\<24 weeks
* Normal liver function
* Able to comprehend and willing to sign the informed consent form

Exclusion Criteria:

* Combined with following infections: hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV) and human immunodeficiency virus (HIV)
* Got antiviral treatments before 24 weeks of Gestation
* Got immunosuppressor treatment and/or steroids
* Got diagnosis of cirrhosis,hepatocellular carcinoma or severe hepatitis B
* Got serious obstetric complications
* Got evidence of fetal deformity diagnosed by four-dimensional color Doppler ultrasound examination
* Biological father of infant had HBV infection
Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers

The study is being conducted to explore the safety and tolerability of CoVaccine HT in healthy male and female volunteers. In this study volunteers will receive intramuscular injections of CoVaccine HT.


Eligibility Criteria:
Inclusion Criteria:

* Adult males or females of non child-bearing potential aged 25 to 65 years inclusive and between 19 and 35 kg/m2 body mass index (BMI)
* Generally healthy as determined by pre study medical history, physical examination, 12 lead ECG.
* Negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) I and II tests at screening and rapid influenza diagnostic test at admission.

Exclusion Criteria:

* History of alcohol abuse in the last 5 years or drug abuse at any time, current significant alcohol consumption.
* Fever, active infections (such as influenza) and acute gastrointestinal symptoms following prior to first dosing
* Subjects with a previous serious reaction to a vaccine, such as angioedema or anaphylaxis
Efficacy of Smoking Cessation Intervention for Head and Neck Cancer Patients

The purpose of this study is to determine whether a brief smoking ENT-resident-based intervention increased smoking cessation in patients with Head and Neck cancer attending a Lebanese university hospital, as compared with usual care.

The primary objective of the study is to evaluate the effectiveness of a brief smoking physician-based intervention on smoking-cessation rates in Head and Neck cancer adult patients. The secondary objective is to assess predictors of long-term smoking cessation in such patients.

After an initial assessment of demographic, clinical and smoking characteristics, the patients are randomised (based on a computer randomisation program) in 2 groups:

* Group 1 will receive the usual care in Lebanon, which consists of a brief advice to quit (10 seconds)
* Group 2 will receive a brief (10-15 minutes) standardised smoking cessation counseling session peri-operatively (immediately before or after surgery), by an ENT residents, based on the 5 "A"'s motivational interviewing model:
* Ask (screen for tobacco use)
* Advise (provide a personalised and strong quit message)
* Assess (evaluate the smoker's willingness and readiness to quit)
* Assist (provide cessation counseling, pharmacotherapy, self-help guides)
* Arrange (for followup to prevent relapse, and evaluate cessation progress) A motivational gadget will be distributed to group 2 patients. They will also be offered nicotine replacement therapy (nicotine transdermal patches) for a total of 8 weeks. This will be followed by a telephone boost session after 6 weeks.

The follow-up at 3, 6 and 12 months will be done, for the 2 groups, by a person not implicated in either the randomisation or the intervention (single-blind), in person or, if impossible, by telephone.

Eligibility Criteria:
Inclusion Criteria:

* Head and Neck cancer
* Patients hospitalised from biopsy or surgery
* Current smokers = smokers in the past 3 months
* Reachable by phone

Exclusion Criteria:

* Nonsmokers in the past 3 months
* Current drug dependance
* Pregnant women
* Psychiatric conditions
* Patients under current smoking cessation intervention
Dexamethasone and Lower Extremity Block Duration

Dexamethasone has shown to prolong upper extremity blocks. No one ha studied its effect on lower extremity blocks. The study would evaluate that point.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-75
2. foot surgery
3. no contraindication to regional anesthesia

Exclusion Criteria:

1. opioid dependent
2. chronic pain condition
3. peripheral neuropathy
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Atripla (ATP: FTC/TDF/EFV) was the first single pill treatment for HIV and was the most prescribed first-line treatment from approximately 2008 to 2013 for people infected with HIV. However, ATP has not been recommended as a "preferred" treatment for HIV since 2015, due to there now being single pill treatments that work better. There are a lot of people who are still taking ATP and it is working for them. However, it has the potential to cause serious side effects (chronic kidney disease and fractures and serious neurological effects). These side effects are caused by components in ATP (namely the TDF and EFV parts). Also, the efavirenz (EFV) component is not compatible for treatment of Hepatitis C (HCV) - which is often also seen in people who have HIV. For these reasons, there is a need to find a better alternative treatment for these people currently being treated with ATP.

B/F/TAF (bictegravir/FTC/TAF) is an investigational single pill drug treatment drug that contains neither TDF nor EFV. This study is looking at whether changing people to this new drug treatment will continue to suppress their HIV and have fewer side effects.

Eligibility Criteria:
Inclusion Criteria:

1. HIV-1 seropositive
2. Age \> 21 years
3. Receiving ATP \> 2 years as their only ART, with HIV-1 RNA \< 50 copies/mL at screening and all HIV-1 RNA tests \< 100 copies/mL in the past 18 months
4. No documented resistance mutations to the components of ATP
5. Any CD4 count, but no active AIDS-defining opportunistic infections or cancers
6. HBsAg+ permitted if plasma HBV DNA is unquantifiable and the patient does not have decompensated liver disease

Exclusion Criteria:

1. Pregnancy, breastfeeding or planned pregnancy in the next 2 years
2. Documented resistance to the components of ATP
3. Active AIDS-defining opportunistic infection or cancer
4. Cancer in past 3 years, except non melanoma skin cancer
5. Active psychotic disease or active depression that may interfere with study participation according investigator discretion
6. Any illness with a life expectancy less than 2 years
7. eGFR \< 50 mL/min
8. Urine protein/creatinine \> 40 mg/mmoL
9. Patients who the investigator feels are unlikely to commit to the study requirements for any reason
10. Prescription drug therapy for osteoporosis (calcium and/or vitamin D is allowed)
PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Evaluation of the PicoWay™ Laser System With 730nm and Resolve™ Fusion Handpieces for Treatment of Benign Pigmented Lesions and Wrinkles.

Subjects will receive up to 4 study treatments with the PicoWay™ 730 nm laser wavelength, PicoWay™1064nm fractional handpiece and/or PicoWay™ 1064nm fractional handpiece for treatment of benign pigmented lesions or wrinkles. Subjects will return for three follow-up visit evaluations 1-month, 2-months and 3-months post final study treatment. Primary efficacy assessed by masked photographic evaluation. Optional biopsy collection for histological analysis of laser tissue effects.

Eligibility Criteria:
Inclusion Criteria

1. Willing to provide signed informed consent
2. Adults age 21 to 80
3. Fitzpatrick Skin Type (FST) I to VI
4. Presence of benign pigmented Lesions assessed at baseline as Pigment Severity Score (PSS) of "2" or higher and/or wrinkles assessed at baseline as Fitzpatrick Wrinkle Score (FWS) of "2" or higher
5. Willing to allow photographs and/or video to be taken of treated areas for the purposes of this research study
6. Willing to abstain from any other procedures for treatment of benign pigmented lesions or wrinkles in the laser treatment areas for the duration of the study including surgery, light, laser, ultrasound or radiofrequency treatments
7. Willing to abstain from use of prescription cosmetic products for treatment of benign pigmented lesions or wrinkles in the laser treatment areas for the duration of the study including injections of neurotoxins or dermal fillers, skin lightening creams, and wrinkle creams
8. Willingness to adhere to study treatment and follow-up visit schedules

Exclusion Criteria

1. Pregnant, planning pregnancy or breast feeding
2. Allergy to topical or injectable lidocaine or similar medications
3. Allergy to topical steroid or similar medications
4. Unprotected sun exposure in the six weeks prior to enrollment, or active tan in the laser treatment area
5. History of melanoma in the intended treatment area
6. History of keloid or hypertrophic scar formation
7. Use of topical or systemic retinoid therapy during the past six (6) months
8. Use of neurotoxins in the intended treatment area within the past three (3) months or throughout the duration of the study
9. Use of dermal fillers in the intended treatment area within the last six (6) months or throughout the duration of the study
10. Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment.
11. Open wound or infection in the intended treatment area
12. History of light induced seizure disorders
13. Dermatologic and/or cosmetic procedures in the intended treatment area(s) during the past six months
14. The subject is not suitable, in the opinion of the clinician, for participation in the study due to medical or other reasons that could compromise the study integrity or subject safety
Determinants of Functional Ability, Perceived Health, and Interaction With Multimorbidity in Hip and Knee Osteoarthritis

Hip and knee osteoarthritis (OA) is an important health problem with a high prevalence and significant consequences on functional ability, perceived health, restriction of autonomy and handicap. The weight of multimorbidities and their interaction on functional ability and perceived health are left unexplored. This project will rely on the cohort KHOALA, representative, multiregional, of 881 prevalent cases (symptomatic hip and knee OA).

Main objective:

* to describe the evolution over time of pain, functional ability, social participation and quality of life in subjects with hip and knee OA
* to identify prognosis factors of disease evolution (socio-demographic, clinical, and other health parameters)
* to determine interactions with comorbidities, other personal and environmental factors (ICF model).

Concurrent objective: to improve measurement of perceived health specific to hip and knee OA by the OAKHQOL by improving its metrologic performances based on item response theory.

Task 1: To prepare an improved measurement scale, available as a judgment criteria for the 3rd year of cohort follow up, over the april 2010-march 2012 period, the mini-OAKHQOL Task 2: Evaluation of the cohort in 2010-2012 (year 3 of follow up) in a repeated measure design to best assess the evolution of perceived health and functional ability over time, and to identify stability of deterioration of autonomy. Perspectives: This project targets to provide public health deciders with information of good quality to help them manage determinants of perceived health in OA subjects, as essential factors to health care resource utilization in their various modalities.


Eligibility Criteria:
Inclusion Criteria:

* hip or knee osteoarthritis (tibiofemoral), uni or bilateral, symptomatic, with confirmed diagnosis according to American College of Rheumatology ACR and European League Against Rheumatism (EULAR)
* Kellgren and Laurence radiological stage at least 2

Exclusion Criteria:

* knee or hip prosthesis on painful joint
* preceding osteotomy
* serious comorbidity (affecting quality of life, or leading to a high care consumption)
* according to X-ray : knee pain with isolated patello-femoral osteoarthritis (i.e without an associated tibiofemoral osteoarthritis)
* other pathology on knee or hip
* adults getting a legal protection or with the incapacity to give their consent
Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section

In obstetrics, postpartum haemorrhage (PPH) continues to be a major contributor to maternal morbidity and mortality worldwide. Uterine atony is the most common cause of PPH, and the prophylactic use of uterotonics, specifically oxytocin, is the standard of care for PPH prophylaxis. It is believed that tranexamic acid (TXA) can enhance the hemostatic process further by inhibiting the fibrinolytic system.

TXA is an antifibrinolytic that has been studied in many different patient population for its use in reducing blood loss ranging from gynaecological and non gynaecological surgeries, to trauma patients. It has been found to reduce mortality in treatment of patients with PPH, and recent evidence have found promising results in its use for prophylaxis of PPH.


Eligibility Criteria:
Inclusion Criteria:

* All English speaking patients
* Above 21 year old
* Undergoing elective caesarean section.

Exclusion Criteria:

* Known/suspected placenta accreta antenatally
* Contraindications to syntocinon and tranexamic acid such as hypersensitivity to these medications
* Known thrombophilia or coagulopathy
* History of thromboembolic events
* Severe cardiac/renal/liver disease
* Poorly controlled hypertension /severe preeclampsia (BP \> 160/100)/eclampsia
Primovist Regulatory Post Marketing Surveillance (PMS)

The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice


Eligibility Criteria:
Inclusion Criteria:

* Patient who take Primovist for liver MRI

Exclusion Criteria:

* Patients who belong to the contraindication on the product label